SAN FRANCISCO--(BUSINESS WIRE)--Jan. 30, 2019--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA,
today announced that Bill Peck, Ph.D., chief technology officer,
participated in the Future Health Threats Initiative 2019, a conference
designed to encourage public-private cooperation to strengthen health
security in Africa. The workshop was focused on bio-IT and genomics. The
conference was held January 28-29 in Leuven, Belgium.
About the Praesens Foundation and the Future Health Threats Initiative
The Praesens Foundation is operating at the intersection of global
health technology innovation and social impact. It has the privilege to
collaborate with a broad network of professionals who are passionate
about what they do and can act as a rallying point for impactful
initiatives. Driven by its field experiences in Africa and aiming for
tangible outcomes, it is uniquely positioned to have hosted and
coordinated this meeting by creating a working space and interface where
individuals and organizations could exchange ideas freely, pool assets
and resources and agree on how to execute upon a common vision to
strengthen surveillance, disease intelligence, and health information
exchange. This will be in support of Africa CDC’s mission that envisions
a safer, healthier, integrated and stronger Africa, whereby Member
States are capable of effectively responding to outbreaks of infectious
diseases and other public health threats. The Future Health Threats
Initiative is championing interdisciplinary problem-solving and the
Praesens Foundation aims to bring together the best in class, who are
fostering innovation, digital transformation and bio-informatics in
order to have a better overall picture of health and information at hand.
About Twist Bioscience Corporation
Twist is a leading and rapidly growing synthetic biology company that
has developed a disruptive DNA synthesis platform to industrialize the
engineering of biology. The core of its platform is a proprietary
technology that pioneers a new method of manufacturing synthetic DNA by
“writing” DNA on a silicon chip. Twist is leveraging its unique
technology to manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing (NGS)
preparation, and antibody libraries for drug discovery and development.
Twist is also pursuing longer-term opportunities in digital data storage
in DNA and biologics drug discovery. Twist makes products for use across
many industries including healthcare, industrial chemicals, agriculture
and academic research.
Follow us on Twitter
| Facebook
| LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20190130005189/en/
Source: Twist Bioscience Corporation
Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com